Compare Dropbox Inc (DBX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Summit Therapeutics Inc — how do they compare? Dropbox Inc trades at $33.64 (market cap $7.41B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Dropbox Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DBX | SMMT | |
|---|---|---|
Market Cap | $7.41B | $12.06B |
Sector | Technology | Health |
52-Week High | $35.00 | $26.98 |
52-Week Low | $22.06 | $12.55 |
Enterprise Value | $10.27B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.79, down 2.31% today, but maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.75, exceeding expectations, and raised its full-year outlook. Strong profitability margins and positive cash flow trends support fundamentals, though negative shareholder equity and high debt levels present financial risks. Analyst sentiment is mixed with a balanced buy/hold/sell distribution.
The outlook for DBX is cautiously optimistic, driven by earnings momentum and AI expansion, but investors face risks from leveraged balance sheets and competitive pressures. Upside potential hinges on sustained core business growth, while downside risks include debt servicing and market volatility. The stock offers growth appeal but requires monitoring of financial health.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
